T-DXd was recently also evaluated in a pan-cancer cohort leading to the tumor-agnostic approval of this ADC for all patients with solid tumors that show high (3+) HER2 expression on standardized IHC assessment (13, 14). Here, ERBB2 is linked to neoplasm.